Repligen Corporation, a life sciences company, engages in the development, production, and commercialization of consumable products used in the process of manufacturing biological drugs. Its bioprocessing products are sold to various life sciences and biopharmaceutical companies worldwide. The company manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. It also supplies various growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, the company develops and markets its OPUS brand series of pre-packed plug-and-play' chromatography columns, and provides ELISA test kits to ensure final product quality. Further, Repligen has a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and a orphan drug candidate in Phase 1 development. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Address
Building #1, Suite 100, 41 Seyon Street
WALTHAM, MA 02453
United States
WALTHAM, MA 02453
United States
Website
http://www.repligen.comKey stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | 31.28% | 22.73% |
| Operating margin | 42.73% | 17.80% |
| EBITD margin | - | 23.91% |
| Return on average assets | 21.84% | 16.36% |
| Return on average equity | 24.52% | 18.86% |
| Employees | 120 |
No comments:
Post a Comment